Paracoccidioidomycosis is a neglected systemic endemic mycosis caused by the dimorphic fungus Paracoccidioides spp. (primarily P. brasiliensis and P. lutzii), endemic to Latin America (especially Brazil), acquired via inhalation of airborne conidia, and presenting as either an acute/subacute (juvenile) or chronic (adult) form with predilection for the lungs, oropharyngeal mucosa, lymph nodes, skin, and adrenal glands. [1-2]
1. History
- Travel/residence history: Current or prior residence in endemic areas of Central/South America — reactivation can occur up to 50 years after leaving the endemic area [2]
- Occupation: Agricultural or rural work with soil exposure (69% of cases in one series were agricultural workers) [3]
- Symptom characterization: Chronic cough, dyspnea, sputum production, oral/pharyngeal pain, hoarseness, odynophagia, skin lesions, weight loss
- Timing: Chronic form evolves over months to years; acute/juvenile form evolves rapidly over 15 days to 3 months [2]
- Associated symptoms: Fever, night sweats, weight loss, lymphadenopathy, oral ulcers (mulberry-like or moriform stomatitis)
- Important negatives: Rule out hemoptysis (TB overlap), neurological symptoms (CNS involvement), postural hypotension (adrenal insufficiency)
2. Alarm Features
- Acute/juvenile form with rapid dissemination (hepatosplenomegaly, generalized lymphadenopathy, ascites) — untreated, this is uniformly fatal [2]
- Signs of adrenal insufficiency (hypotension, hyperpigmentation, electrolyte abnormalities) — Addison's syndrome is a known complication [2]
- CNS involvement: Seizures, focal neurological deficits, paresis — granulomatous brain/spinal cord lesions [4]
- Marked eosinophilia (>25,000 cells/mm³) in pediatric cases is strongly associated with mortality [5]
- Hepatosplenomegaly in the juvenile form (present in 86% of fatalities vs. 22% of survivors) [5]
- Respiratory failure from extensive pulmonary involvement
- Lymph node fistulization (27% of pediatric cases, associated with poorer prognosis) [5]
3. Medications
- First-line (mild-to-moderate): Itraconazole 200 mg daily for 9–18 months — efficacy rate ~86–91%; superior to TMP-SMX in cure rate (86.4% vs. 51.3%) and time to clinical cure (105 vs. 159 days) [6-8]
- Second-line: TMP-SMX (co-trimoxazole) for 18–24 months — fungistatic only, longer treatment required; adequate response in ~74% with good adherence [2][9]
- Severe/disseminated disease: Amphotericin B (2–4 weeks induction) → step-down to itraconazole 200–400 mg daily [2][6]
- CNS involvement: Voriconazole 6 mg/kg/day for 6–12 months (or fluconazole) due to better CNS penetration [6][10]
- Cautions: Itraconazole has significant drug interactions (CYP3A4); subtherapeutic levels are common with capsule formulations — therapeutic drug monitoring (TDM) may be warranted in selected cases. Avoid itraconazole in pregnancy. [11]
4. Diet
- No specific dietary triggers
- Ensure adequate nutrition — malnutrition is common in affected populations and worsens outcomes
- Itraconazole capsules should be taken with food or an acidic beverage (cola) to enhance absorption; avoid concurrent use of antacids, PPIs, or H2 blockers
- Long-term alcohol avoidance is advisable given hepatotoxicity risk of prolonged azole therapy
5. Review of Systems
- Pulmonary: Cough, dyspnea, sputum, hemoptysis
- ENT/Oral: Oral pain, hoarseness, dysphagia, nasal obstruction — oral mucosal lesions are present in ~90% of chronic cases [12]
- Dermatologic: Skin papules, nodules, ulcers, verrucous lesions
- Constitutional: Fever, weight loss, night sweats, fatigue
- Endocrine: Symptoms of adrenal insufficiency (fatigue, dizziness, hyperpigmentation, salt craving)
- Neurologic: Headache, seizures, focal deficits (CNS dissemination)
- GI/Hepatic: Abdominal pain, hepatomegaly, ascites (juvenile form)
- Musculoskeletal: Bone pain (osteomyelitis in ~16% of pediatric cases) [5][13]
6. Collateral History and Family History
- Detailed geographic history is critical — even remote travel to endemic areas decades prior [2]
- Occupational exposure to soil (farming, construction, excavation)
- No person-to-person transmission — no isolation required
- Family members with similar exposures may also be infected (shared environmental risk, not genetic)
- HIV status and immunosuppressive medication use
7. Risk Factors
- Residence/travel in endemic Latin American regions (Brazil accounts for ~80% of cases) [8]
- Male sex — chronic form has a male-to-female ratio of 13–20:1; estradiol inhibits the mycelium-to-yeast conversion, protecting women [2][6]
- Rural/agricultural occupation with soil contact [6]
- Smoking and alcohol use — associated with chronic pulmonary form
- Immunosuppression: HIV/AIDS, organ transplant, corticosteroid use
- Age: Chronic form in adults 30–60 years; juvenile form in children/adolescents [6]
- Malnutrition and low socioeconomic status [14]
8. Differential Diagnosis
- Pulmonary tuberculosis — most important mimic; co-infection is common [10][15]
- Histoplasmosis — similar endemic mycosis with overlapping geography and presentation [2]
- Squamous cell carcinoma — oral/laryngeal mucosal lesions can closely mimic PCM [10]
- Hodgkin/non-Hodgkin lymphoma — especially in the juvenile form with diffuse lymphadenopathy [16]
- Sarcoidosis — granulomatous disease with pulmonary and multisystem involvement [2]
- Mucocutaneous leishmaniasis — overlapping endemic areas; nasal lesions favor leishmaniasis, oral lesions favor PCM [12]
- Other endemic mycoses: Coccidioidomycosis, blastomycosis, sporotrichosis
- Leukemia — in pediatric cases with hepatosplenomegaly and cytopenias [16]
9. Past Medical History
- Prior episodes of PCM (relapses occur up to 5 years after apparent cure) [1]
- Previous TB or TB treatment (co-infection is common)
- HIV/AIDS status
- Chronic lung disease (COPD, smoking history)
- Adrenal insufficiency (may be a sequela of prior PCM)
- Prior immunosuppressive therapy
- Surgical history (prior biopsies of suspicious lesions)
10. Physical Exam
- Vital signs: Fever, tachycardia; hypotension if adrenal crisis
- Oropharynx: Mulberry-like (moriform) ulcers of the gingiva, palate, lips, pharynx, and larynx — pathognomonic "mulberry stomatitis" with hemorrhagic punctate dots
- Lymph nodes: Generalized or regional lymphadenopathy; may be suppurative or fistulizing
- Lungs: Crackles, decreased breath sounds, signs of consolidation or fibrosis
- Skin: Papules, nodules, ulcerated or verrucous plaques (face, extremities)
- Abdomen: Hepatosplenomegaly (especially juvenile form)
- Neurologic: Focal deficits, signs of increased ICP if CNS involvement
- Endocrine: Hyperpigmentation (Addisonian features)
- Nasal/laryngeal: Hoarseness, nasal septal perforation (less common than in leishmaniasis) [12]
11. Lab Studies
- CBC: Anemia, eosinophilia (marked in juvenile form — >25,000/mm³ is a poor prognostic sign); leukocytosis [5]
- ESR/CRP: Elevated; ESR normalization is used as a treatment response marker [7]
- Serology: Immunodiffusion assay — specificity >95%, sensitivity ~80%; quantitative titers correlate with disease severity and can monitor treatment response [6]
- Direct microscopy (KOH/optical brighteners): Pathognomonic "pilot wheel" or "ship wheel" yeast with multiple buds (15–30 μm, up to 60 μm) [6]
- Fungal culture: Incubate at 25–30°C for 4–8 weeks; may be negative [6]
- Histopathology: Granulomatous inflammation with characteristic multi-budding yeast
- Electrolytes, cortisol, ACTH: Screen for adrenal insufficiency
- LFTs: Baseline and monitoring during azole therapy
- HIV testing: All confirmed cases
- Rule out TB: AFB smear/culture, tuberculin skin test or IGRA
12. Imaging
- Chest X-ray/CT (first-line): Bilateral, symmetric, mixed alveolar-interstitial infiltrates ("butterfly wing" pattern); granulomatous nodules that may cavitate but rarely calcify; fibrotic changes in chronic disease [15]
- Juvenile form: Hilar/mediastinal lymphadenopathy, unilateral pleural effusion, miliary-like shadows [15]
- CT abdomen: Hepatosplenomegaly, abdominal lymphadenopathy (juvenile form)
- Brain MRI (if CNS symptoms): Granulomatous lesions, meningeal enhancement, hydrocephalus [4]
- Skeletal imaging: Lytic bone lesions if osteomyelitis suspected [13]
- Imaging alone is nonspecific — always correlate with microbiologic/serologic confirmation
13. Special Tests
- Immunodiffusion (ID) assay: Reference standard serologic test; performed at reference laboratories [6]
- Complement fixation: Alternative serologic method
- PCR: Used in some centers but not fully validated or standardized [2]
- Antigen detection: Not yet commercially available [6]
- Biopsy with histopathology: GMS or PAS staining reveals characteristic multi-budding yeast
- Lymph node aspirate: Higher sensitivity than sputum for direct microscopy [2]
- Cosyntropin stimulation test: If adrenal insufficiency suspected
- Itraconazole TDM: Target trough 0.5–4.0 mg/L; subtherapeutic levels are common (only 44% within range in one study) [11]
14. ECG
- Not routinely indicated unless:
- Adrenal crisis suspected (hyperkalemia → peaked T waves, widened QRS)
- Amphotericin B use (monitor for hypokalemia-related changes: U waves, QT prolongation)
- Azole-related QT prolongation (voriconazole)
15. Assessment
Two major clinical forms
- Acute/subacute (juvenile) form (~10% of cases): Rapid onset, disseminated lymphadenopathy, hepatosplenomegaly, fever, weight loss, eosinophilia; affects children/adolescents of both sexes; high mortality if untreated [2][6]
- Chronic (adult) form (~90% of cases): Insidious onset over months to years; predominantly adult males (M:F 13–20:1); involves lungs, oropharyngeal mucosa, skin, lymph nodes, adrenal glands [2][6]
Severity stratification
- Mild-to-moderate: Localized pulmonary and/or mucosal disease, stable vitals, able to take oral medications
- Severe: Disseminated multiorgan involvement, CNS disease, respiratory failure, adrenal crisis, immunocompromised host
Complications (even after treatment): Pulmonary fibrosis, microstomy, Addison's syndrome, neurological impairment [2]
16. Treatment Plan
Initial stabilization (severe cases)
- IV amphotericin B (deoxycholate or lipid formulation) for 2–4 weeks induction [6]
- Manage adrenal crisis if present (IV hydrocortisone, fluid resuscitation)
- Transition to oral itraconazole 200–400 mg/day after clinical improvement [6]
Mild-to-moderate disease
- Itraconazole 200 mg PO daily for 9–18 months (take with food; avoid PPIs) [6]
- Alternative: TMP-SMX (800/160 mg BID) for 18–24 months if itraconazole unavailable or contraindicated [6]
CNS disease
Treatment endpoints
- Clinical resolution of signs/symptoms
- Normalization of ESR
- Serological cure: Negative or significantly decreased antibody titers on immunodiffusion [7]
- Treatment should not be stopped based on clinical improvement alone — serologic cure is required
17. Disposition
Admit if
- Severe/disseminated disease requiring IV amphotericin B
- Acute/juvenile form with systemic toxicity
- Respiratory failure or hemodynamic instability
- Suspected adrenal crisis
- CNS involvement
- Inability to tolerate oral medications
Discharge criteria
- Clinically stable on oral therapy
- Tolerating itraconazole or TMP-SMX
- Outpatient infectious disease follow-up arranged
Specialist consultation
- Infectious disease — all confirmed/probable cases
- Pulmonology — significant pulmonary involvement or fibrosis
- Endocrinology — adrenal insufficiency
- Neurosurgery/Neurology — CNS lesions with mass effect or hydrocephalus
- ENT — laryngeal involvement, microstomy
18. Follow Up / Return Precautions
- Follow-up timing: Monthly initially, then every 2–3 months; serologic titers should be monitored every 3–6 months to guide treatment duration [6-7]
- Treatment duration: Minimum 9–12 months (itraconazole) or 18–24 months (TMP-SMX); do not discontinue until serologic cure is confirmed
- Relapse risk: Relapses may occur up to 5 years after apparent cure — long-term surveillance is essential [1]
- Return precautions: Worsening cough, dyspnea, new skin lesions, oral ulcers, fever, dizziness/syncope (adrenal insufficiency), seizures or focal weakness (CNS relapse)
- Patient counseling: Emphasize medication adherence — nonadherence is the strongest predictor of treatment failure; itraconazole must be taken with food; avoid alcohol; report GI symptoms or jaundice (hepatotoxicity monitoring) [9]
- Expected course: Clinical improvement typically within weeks to months; pulmonary fibrosis and other sequelae may persist despite microbiologic cure [2]
References
1. Paracoccidioidomycosis: Current Status and Future Trends. — Hahn RC, Hagen F, Mendes RP, et al. Clinical Microbiology Reviews. 2022.
2. Neglected Endemic Mycoses. — Queiroz-Telles F, Fahal AH, Falci DR, et al. The Lancet. Infectious Diseases. 2017.
3. New Clinical and Genomic Insights Into Paracoccidioidomycosis in Paraguay: A Neglected Endemic Area. — Chamorro Correa LR, Kollath DR, Guerra Tenório B, et al. Medical Mycology. 2026.
4. Advances in the Diagnosis and Treatment of Fungal Infections of the CNS. — Schwartz S, Kontoyiannis DP, Harrison T, Ruhnke M. The Lancet. Neurology. 2018.
5. Paracoccidioidomycosis in Childhood and Adolescence: Clinical-Epidemiological Review of South American Cases (1970-2023). — de Siqueira NPL, da Silva Pinto G, Ueda CY, et al. Mycopathologia. 2025.
6. Global Guideline for the Diagnosis and Management of the Endemic Mycoses: An Initiative of the European Confederation of Medical Mycology in Cooperation With the International Society for Human and Animal Mycology. — Thompson GR, Le T, Chindamporn A, et al. The Lancet. Infectious Diseases. 2021.
7. Comparison Between Itraconazole and Cotrimoxazole in the Treatment of Paracoccidiodomycosis. — Cavalcante Rde S, Sylvestre TF, Levorato AD, de Carvalho LR, Mendes RP. PLoS Neglected Tropical Diseases. 2014.
8. Itraconazole vs. Trimethoprim-Sulfamethoxazole: A Comparative Cohort Study of 200 Patients With Paracoccidioidomycosis. — Borges SR, Silva GM, Chambela Mda C, et al. Medical Mycology. 2014.
9. Therapeutic Response in Adult Patients With Nonsevere Chronic Paracoccidioidomycosis Treated With Sulfamethoxazole-Trimethoprim: A Retrospective Study. — Nery AF, Crepaldi NP, Rossi SBRS, et al. The American Journal of Tropical Medicine and Hygiene. 2017.
10. Paracoccidioidomycosis. — Marques SA. Clinics in Dermatology. 2012.
11. Therapeutic Drug Monitoring of Itraconazole in Endemic Paracoccidioidomycosis: Real-World Data. — Kruschewsky WLL, de Freitas VLT, Taborda M, et al. Mycopathologia. 2025.
12. Differentiation of Mucosal Lesions in Mucocutaneous Leishmaniasis and Paracoccidioidomycosis. — Vicente CR, Falqueto A. PloS One. 2018.
13. Clinical Patterns of Osteoarticular, Bone Marrow and Urogenital Paracoccidioidomycosis. — Kruschewsky WLL, Stricagnolo MC, Vidal MSM, et al. Mycoses. 2026.
14. Paracoccidioidomycosis in the 21st Century: Challenges and Milestones. — Venturini J, Fernandez NB, de Macedo PM, et al. PLoS Neglected Tropical Diseases. 2026.
15. Pulmonary and Sinus Fungal Diseases in Non-Immunocompromised Patients. — Denning DW, Chakrabarti A. The Lancet. Infectious Diseases. 2017.
16. Paracoccidioidomycosis. — Ferreira MS. Paediatric Respiratory Reviews. 2009.